Full TitleA Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies
This dose-escalation and dose-expansion study randomly assigns patients with advanced renal cell cancer to receive either MEDI0680 alone or in combination with MEDI4736. MEDI4736 is an antibody that targets a protein on tumor and immune cells called PD-L1. MEDI0680 targets a protein on immune cells called PD1.
Both drugs are immunotherapy drugs designed to increase the immune system’s ability to identify and destroy cancer cells. They are both given intravenously (by vein).
To be in this study, patients must:
- Have advanced renal cell cancer that has continued to grow despite one previous regimen of therapy.
- Not have had prior immunotherapy.
- Have an ECOG status of 0 or 1.
- Be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Martin Voss at 646-422-4631.